| Literature DB >> 23652313 |
S-C Kuo1, Y-W Hu, C-J Liu, Y-T Lee, Y-T Chen, T-L Chen, T-J Chen, C-P Fung.
Abstract
BACKGROUND: In addition to lung cancers, tuberculosis infections have been associated with increased risk of non-pulmonary malignancies in case reports. Our population-based study employed standardized incidence ratios (SIRs) to systemically survey non-pulmonary cancer risks after tuberculosis infections.Entities:
Mesh:
Year: 2013 PMID: 23652313 PMCID: PMC3708573 DOI: 10.1038/bjc.2013.220
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Characteristics of patients with tuberculosis diagnosis
| No. of patients | 6699 | 4630 | 2069 |
| Person–years at risk | 28 866 | 19 297 | 9569 |
| Median follow-up, years (interquartile range) | 3.8 (1.3–6.9) | 3.6 (1.2–6.7) | 4.4 (1.4–7.5) |
| Median age, years (interquartile range) | 64.3 (46.7–76.1) | 66.3 (49.5–76.6) | 59.2 (40.2–74.9) |
| 20–39 | 1157 (17.3%) | 644 (13.9%) | 513 (24.8%) |
| 40–59 | 1744 (26.0%) | 1194 (25.8%) | 550 (26.6%) |
| 60–79 | 2739 (40.9%) | 2033 (43.9%) | 706 (34.1%) |
| ⩾80 | 1059 (15.8%) | 759 (16.4%) | 300 (14.5%) |
Standardized incidence ratios (SIRs) of all cancers according to age at cancer diagnosis, gender and follow-up period after tuberculosis diagnosis
| All cancers | 530 | 2.07 (1.90–2.26) | 439 | 2.18 (1.98–2.40) | 91 | 1.67 (1.34–2.05) |
| 20–39 | 17 | 3.87 (2.25–6.20) | 13 | 6.32 (3.37–10.81) | 4 | 1.71 (0.47–4.38) |
| 40–59 | 92 | 2.50 (2.01–3.06) | 68 | 2.73 (2.12–3.47) | 24 | 2.01 (1.29–2.99) |
| 60–79 | 304 | 2.05 (1.83–2.30) | 261 | 2.16 (1.90–2.43) | 43 | 1.59 (1.15–2.15) |
| ⩾ 80 | 117 | 1.76 (1.46–2.11) | 97 | 1.83 (1.48–2.23) | 20 | 1.51 (0.92–2.33) |
| <1 | 240 | 4.59 (4.03–5.21) | 196 | 4.72 (4.08–5.43) | 44 | 4.08 (2.97–5.48) |
| 1–5 | 197 | 1.44 (1.25–1.66) | 165 | 1.52 (1.30–1.78) | 32 | 1.12 (0.77–1.58) |
| > 5 | 93 | 1.40 (1.13–1.71) | 78 | 1.52 (1.20–1.90) | 15 | 0.99 (0.55–1.63) |
| Follow-up ⩾1 year | 290 | 1.43 (1.27–1.60) | 243 | 1.52 (1.34–1.73) | 47 | 1.07 (0.79–1.43) |
Abbreviation: CI=confidence interval.
The age when the cancer was diagnosed.
Standardized incidence ratios (SIRs) of non-pulmonary cancers according to age at cancer diagnosis, gender, and follow-up period after tuberculosis diagnosis
| Non-pulmonary cancers | 371 | 1.71 (1.54–1.90) | 305 | 1.81 (1.61–2.03) | 66 | 1.36 (1.05–1.73) |
| 20–39 | 14 | 3.28 (1.79–5.51) | 11 | 5.54 (2.77–9.91) | 3 | 1.32 (0.27–3.84) |
| 40–59 | 70 | 2.06 (1.61–2.61) | 56 | 2.46 (1.86–3.20) | 14 | 1.26 (0.69–2.11) |
| 60–79 | 199 | 1.60 (1.39–1.84) | 167 | 1.66 (1.42–1.93) | 32 | 1.35 (0.92–1.91) |
| ⩾80 | 88 | 1.62 (1.30–1.99) | 71 | 1.65 (1.29–2.08) | 17 | 1.50 (0.87–2.40) |
| <1 | 134 | 3.03 (2.54–3.59) | 111 | 3.20 (2.64–3.86) | 23 | 2.41 (1.53–3.61) |
| 1–5 | 155 | 1.34 (1.13–1.56) | 126 | 1.39 (1.16–1.66) | 29 | 1.14 (0.76–1.64) |
| >5 | 82 | 1.45 (1.15–1.80) | 68 | 1.58 (1.23–2.00) | 14 | 1.04 (0.57–1.74) |
| Follow-up ⩾1 year | 237 | 1.37 (1.20–1.56) | 194 | 1.45 (1.25–1.67) | 43 | 1.11 (0.80–1.49) |
Abbreviation: CI=confidence interval.
The age when the cancer was diagnosed.
Standardized incidence ratios (SIRs) for specific cancer types among patients with tuberculosis diagnosis
| All cancers | 530 | 2.07 (1.90–2.26) | 439 | 2.18 (1.98–2.40) | 91 | 1.67 (1.34–2.05) |
| Head and neck | 41 | 2.02 (1.45–2.74) | 37 | 1.96 (1.38–2.70) | 4 | 2.77 (0.75–7.08) |
| Digestive | 183 | 1.70 (1.46–1.96) | 156 | 1.78 (1.51–2.09) | 27 | 1.34 (0.88–1.95) |
| Esophagus | 20 | 3.36 (2.05–5.19) | 17 | 3.00 (1.74–4.80) | 3 | 11.07 (2.28–32.37) |
| Stomach | 22 | 1.35 (0.85–2.04) | 18 | 1.33 (0.79–2.10) | 4 | 1.47 (0.40–3.76) |
| Colon and rectum | 57 | 1.40 (1.06–1.82) | 44 | 1.39 (1.01–1.87) | 13 | 1.43 (0.76–2.45) |
| Anus | 0 | 0.00 (0.00–14.12) | 0 | 0.00 (0.00–20.47) | 0 | 0.00 (0.00–45.53) |
| Liver | 66 | 1.84 (1.42–2.34) | 61 | 2.03 (1.55–2.61) | 5 | 0.85 (0.28–1.99) |
| Biliary tract | 11 | 3.14 (1.57–5.62) | 9 | 3.55 (1.62–6.75) | 2 | 2.07 (0.25–7.47) |
| Pancreas | 7 | 1.38 (0.55–2.84) | 7 | 1.80 (0.72–3.71) | 0 | 0.00 (0.00–3.08) |
| Lung | 159 | 4.09 (3.48–4.78) | 134 | 4.09 (3.42–4.84) | 25 | 4.13 (2.67–6.10) |
| Bone and soft tissue | 1 | 0.53 (0.01–2.93) | 1 | 0.67 (0.02–3.71) | 0 | 0.00 (0.00–9.24) |
| Skin cancer | 12 | 2.08 (1.07–3.63) | 11 | 2.62 (1.31–4.69) | 1 | 0.63 (0.02–3.53) |
| Melanoma | 4 | 4.76 (1.30–12.19) | 4 | 6.38 (1.74–16.35) | 0 | 0.00 (0.00–17.27) |
| Non-melanoma | 8 | 1.62 (0.70–3.19) | 7 | 1.96 (0.79–4.04) | 1 | 0.73 (0.02–4.08) |
| Breast | 9 | 0.93 (0.43–1.77) | 0 | 0.00 (0.00–15.93) | 9 | 0.95 (0.44–1.81) |
| Genitourinary | 72 | 1.51 (1.18–1.90) | 62 | 1.61 (1.23–2.06) | 10 | 1.10 (0.53–2.02) |
| Cervix | 3 | 0.95 (0.20–2.79) | 0 | — | 3 | 0.95 (0.20–2.79) |
| Uterus | 3 | 2.17 (0.45–6.35) | 0 | — | 3 | 2.17 (0.45–6.35) |
| Ovary | 1 | 0.79 (0.02–4.38) | 0 | — | 1 | 0.79 (0.02–4.38) |
| Prostate | 32 | 1.34 (0.91–1.89) | 32 | 1.34 (0.91–1.89) | 0 | – |
| Bladder | 22 | 1.95 (1.22–2.96) | 21 | 2.15 (1.33–3.28) | 1 | 0.67 (0.02–3.74) |
| Kidney | 11 | 1.66 (0.83–2.97) | 9 | 1.86 (0.85–3.54) | 2 | 1.12 (0.14–4.03) |
| CNS | 4 | 1.77 (0.48–4.53) | 3 | 1.73 (0.36–5.06) | 1 | 1.89 (0.05–10.51) |
| Thyroid | 2 | 0.81 (0.10–2.92) | 0 | 0.00 (0.00–3.80) | 2 | 1.33 (0.16–4.81) |
| Hematologic malignancies | 26 | 2.30 (1.51–3.38) | 18 | 2.02 (1.20–3.20) | 8 | 3.34 (1.44–6.59) |
| Non-Hodgkin's lymphoma | 11 | 1.95 (0.97–3.49) | 9 | 2.05 (0.94–3.89) | 2 | 1.61 (0.19–5.80) |
| Hodgkin's disease | 2 | 9.94 (1.20–35.91) | 2 | 12.83 (1.55–46.35) | 0 | 0.00 (0.00–81.48) |
| Multiple myeloma | 4 | 2.43 (0.66–6.21) | 3 | 2.28 (0.47–6.65) | 1 | 3.03 (0.08–16.86) |
| Leukemia | 9 | 2.37 (1.08–4.50) | 4 | 1.32 (0.36–3.38) | 5 | 6.49 (2.11–15.15) |
Abbreviations: CI=confidence interval; CNS=central nervous system.
Standardized incidence ratios (SIRs) for specific cancer types stratified by time after tuberculosis diagnosis among male and female patients
| Head and neck | 14 | 3.74 (2.05–6.28) | 15 | 1.48 (0.83–2.44) | 8 | 1.61 (0.69–3.17) |
| Esophagus | 8 | 6.96 (3.01–13.72) | 6 | 1.96 (0.72–4.26) | 3 | 2.05 (0.42–6.00) |
| Colon and rectum | 14 | 2.18 (1.19–3.65) | 18 | 1.06 (0.63–1.68) | 12 | 1.46 (0.75–2.55) |
| Liver | 17 | 2.72 (1.59–4.36) | 31 | 1.90 (1.29–2.70) | 13 | 1.73 (0.92–2.96) |
| Biliary tract | 2 | 3.77 (0.46–13.62) | 5 | 3.66 (1.19–8.54) | 2 | 3.15 (0.38–11.37) |
| Lung | 85 | 12.39 (9.90–15.33) | 39 | 2.21 (1.57–3.02) | 10 | 1.21 (0.58–2.23) |
| Melanoma | 2 | 15.39 (1.86–55.59) | 2 | 5.86 (0.71–21.16) | 0 | 0.00 (0.00–23.77) |
| Bladder | 3 | 1.47 (0.30–4.30) | 9 | 1.71 (0.78–3.24) | 9 | 3.64 (1.67–6.92) |
| Hodgkin's disease | 2 | 58.21 (7.05–210.27) | 0 | 0.00 (0.00–44.57) | 0 | 0.00 (0.00–95.18) |
| Esophagus | 3 | 52.11 (10.75–152.28) | 0 | 0.00 (0.00–25.96) | 0 | 0.00 (0.00–51.79) |
| Lung | 21 | 17.24 (10.67–26.36) | 3 | 0.95 (0.20–2.77) | 1 | 0.60 (0.02–3.34) |
| Leukemia | 2 | 13.14 (1.59–47.45) | 1 | 2.46 (0.06–13.72) | 2 | 9.45 (1.14–34.12) |
Abbreviations: SIR=standardized incidence ratio; CI=confidence interval.